Literature DB >> 22820803

Outcomes following virological failure and predictors of switching to second-line antiretroviral therapy in a South African treatment program.

Victoria Johnston1, Katherine L Fielding, Salome Charalambous, Gavin Churchyard, Andrew Phillips, Alison D Grant.   

Abstract

OBJECTIVES: Without resistance tests, deciding which patients with virological failure should switch to second-line antiretroviral therapy (ART) is difficult. The factors influencing this decision are poorly understood. We assess predictors of switching regimens after virological failure.
DESIGN: Retrospective cohort study using clinical data from a South African ART program with 6-monthly viral load (VL) monitoring.
METHODS: We constructed a dataset of patient visits occurring following first-line virological failure, and used random effects logistic regression (accounting for individual-level and clinic-level clustering) to assess predictors of switching at each visit.
RESULTS: One thousand six hundred sixty-eight patients with virological failure (73% male, mean age 41 years, median CD4 184 cells/mm, mean log10 VL 4.3) contributed 1922 person-years of viremia. 12 months after failure, the cumulative incidence of switching regimen, viral resuppression, or death was 16.9%, 13.2%, and 4.6%, respectively. In adjusted analysis, switching was more likely at the third or subsequent visit after failure; in visits occurring in 2008 versus 2003 to 2007; and in patients with ART experience pre-programme, current high VL or low CD4 count. Switching was less likely in patients with no clinic contact for 4 months, or declining VL. Switching rates varied between clinics with clinic-level clustering evident in the final model (P <0.001).
CONCLUSIONS: Despite 6-monthly virological monitoring and recommendations to switch after adherence interventions and confirmed viremia, patients experienced delayed switching. Individual-level covariates influenced switching but did not account for variable switching rates between clinics, suggesting differences in guideline implementation. In certain circumstances delays may be warranted; however understanding barriers to guideline implementation will limit unnecessary delays.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820803      PMCID: PMC3840925          DOI: 10.1097/QAI.0b013e318266ee3f

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  50 in total

1.  Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.

Authors:  Christian Laurent; Charles Kouanfack; Gabrièle Laborde-Balen; Avelin Fobang Aghokeng; Jules Brice Tchatchueng Mbougua; Sylvie Boyer; Maria Patrizia Carrieri; Jean-Marc Mben; Marlise Dontsop; Serge Kazé; Nicolas Molinari; Anke Bourgeois; Eitel Mpoudi-Ngolé; Bruno Spire; Sinata Koulla-Shiro; Eric Delaporte
Journal:  Lancet Infect Dis       Date:  2011-08-08       Impact factor: 25.071

Review 2.  Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review.

Authors:  Katharina Kranzer; Nathan Ford
Journal:  Trop Med Int Health       Date:  2011-07-01       Impact factor: 2.622

3.  Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.

Authors:  Alessandro Cozzi-Lepri; Andrew N Phillips; Javier Martinez-Picado; Antonella d'Arminio Monforte; Christine Katlama; Ann-Brit Eg Hansen; Andrzej Horban; Johann Bruun; Bonaventura Clotet; Jens D Lundgren
Journal:  J Infect Dis       Date:  2009-09-01       Impact factor: 5.226

4.  Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.

Authors:  Andrew N Phillips; Deenan Pillay; Alec H Miners; Diane E Bennett; Charles F Gilks; Jens D Lundgren
Journal:  Lancet       Date:  2008-04-26       Impact factor: 79.321

5.  Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database.

Authors:  Preeyaporn Srasuebkul; Poh Lian Lim; Man Po Lee; Nagalingeswaran Kumarasamy; Jialun Zhou; Thira Sirisanthana; Patrick C K Li; Adeeba Kamarulzaman; Shinichi Oka; Praphan Phanuphak; Saphonn Vonthanak; Tuti P Merati; Yi-Ming A Chen; Somnuek Sungkanuparph; Goa Tau; Fujie Zhang; Christopher K C Lee; Rossana Ditangco; Sanjay Pujari; Jun Y Choi; Jeffery Smith; Matthew G Law
Journal:  Clin Infect Dis       Date:  2009-04-01       Impact factor: 9.079

6.  Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.

Authors:  Catherine Orrell; Guy Harling; Stephen D Lawn; Richard Kaplan; Matthew McNally; Linda-Gail Bekker; Robin Wood
Journal:  Antivir Ther       Date:  2007

7.  Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.

Authors:  Catherine Seyler; Christiane Adjé-Touré; Eugène Messou; Nicole Dakoury-Dogbo; François Rouet; Delphine Gabillard; Monica Nolan; Siaka Toure; Xavier Anglaret
Journal:  AIDS       Date:  2007-05-31       Impact factor: 4.177

8.  Evaluation of WHO Criteria for Viral Failure in Patients on Antiretroviral Treatment in Resource-Limited Settings.

Authors:  Barbara Castelnuovo; Joseph Sempa; Kiragga N Agnes; Moses R Kamya; Yukari C Manabe
Journal:  AIDS Res Treat       Date:  2011-04-10

9.  Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.

Authors:  P Mugyenyi; A S Walker; J Hakim; P Munderi; D M Gibb; C Kityo; A Reid; H Grosskurth; J H Darbyshire; F Ssali; D Bray; E Katabira; A G Babiker; C F Gilks; H Grosskurth; P Munderi; G Kabuye; D Nsibambi; R Kasirye; E Zalwango; M Nakazibwe; B Kikaire; G Nassuna; R Massa; K Fadhiru; M Namyalo; A Zalwango; L Generous; P Khauka; N Rutikarayo; W Nakahima; A Mugisha; J Todd; J Levin; S Muyingo; A Ruberantwari; P Kaleebu; D Yirrell; N Ndembi; F Lyagoba; P Hughes; M Aber; A Medina Lara; S Foster; J Amurwon; B Nyanzi Wakholi; J Whitworth; K Wangati; B Amuron; D Kajungu; J Nakiyingi; W Omony; K Fadhiru; D Nsibambi; P Khauka; P Mugyenyi; C Kityo; F Ssali; D Tumukunde; T Otim; J Kabanda; H Musana; J Akao; H Kyomugisha; A Byamukama; J Sabiiti; J Komugyena; P Wavamunno; S Mukiibi; A Drasiku; R Byaruhanga; O Labeja; P Katundu; S Tugume; P Awio; A Namazzi; G T Bakeinyaga; H Katabira; D Abaine; J Tukamushaba; W Anywar; W Ojiambo; E Angweng; S Murungi; W Haguma; S Atwiine; J Kigozi; L Namale; A Mukose; G Mulindwa; D Atwiine; A Muhwezi; E Nimwesiga; G Barungi; J Takubwa; S Murungi; D Mwebesa; G Kagina; M Mulindwa; F Ahimbisibwe; P Mwesigwa; S Akuma; C Zawedde; D Nyiraguhirwa; C Tumusiime; L Bagaya; W Namara; J Kigozi; J Karungi; R Kankunda; R Enzama; A Latif; J Hakim; V Robertson; A Reid; E Chidziva; R Bulaya-Tembo; G Musoro; F Taziwa; C Chimbetete; L Chakonza; A Mawora; C Muvirimi; G Tinago; P Svovanapasis; M Simango; O Chirema; J Machingura; S Mutsai; M Phiri; T Bafana; M Chirara; L Muchabaiwa; M Muzambi; J Mutowo; T Chivhunga; E Chigwedere; M Pascoe; C Warambwa; E Zengeza; F Mapinge; S Makota; A Jamu; N Ngorima; H Chirairo; S Chitsungo; J Chimanzi; C Maweni; R Warara; M Matongo; S Mudzingwa; M Jangano; K Moyo; L Vere; N Mdege; I Machingura; E Katabira; A Ronald; A Kambungu; F Lutwama; I Mambule; A Nanfuka; J Walusimbi; E Nabankema; R Nalumenya; T Namuli; R Kulume; I Namata; L Nyachwo; A Florence; A Kusiima; E Lubwama; R Nairuba; F Oketta; E Buluma; R Waita; H Ojiambo; F Sadik; J Wanyama; P Nabongo; J Oyugi; F Sematala; A Muganzi; C Twijukye; H Byakwaga; R Ochai; D Muhweezi; A Coutinho; B Etukoit; C Gilks; K Boocock; C Puddephatt; C Grundy; J Bohannon; D Winogron; D M Gibb; A Burke; D Bray; A Babiker; A S Walker; H Wilkes; M Rauchenberger; S Sheehan; C Spencer-Drake; K Taylor; M Spyer; A Ferrier; B Naidoo; D Dunn; R Goodall; J H Darbyshire; L Peto; R Nanfuka; C Mufuka-Kapuya; P Kaleebu; D Pillay; V Robertson; D Yirrell; S Tugume; M Chirara; P Katundu; N Ndembi; F Lyagoba; D Dunn; R Goodall; A McCormick; A Medina Lara; S Foster; J Amurwon; B Nyanzi Wakholi; J Kigozi; L Muchabaiwa; M Muzambi; I Weller; A Babiker; S Bahendeka; M Bassett; A Chogo Wapakhabulo; J H Darbyshire; B Gazzard; C Gilks; H Grosskurth; J Hakim; A Latif; C Mapuchere; O Mugurungi; P Mugyenyi; C Burke; S Jones; C Newland; G Pearce; S Rahim; J Rooney; M Smith; W Snowden; J-M Steens; A Breckenridge; A McLaren; C Hill; J Matenga; A Pozniak; D Serwadda; T Peto; A Palfreeman; M Borok; E Katabira
Journal:  Lancet       Date:  2009-12-08       Impact factor: 79.321

10.  Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD).

Authors:  Preeyaporn Srasuebkul; Alexandra Calmy; Jialun Zhou; Nagalingeswaran Kumarasamy; Matthew Law; Poh Lian Lim
Journal:  AIDS Res Ther       Date:  2007-09-17       Impact factor: 2.250

View more
  27 in total

1.  Sustainable HIV treatment in Africa through viral-load-informed differentiated care.

Authors:  Andrew Phillips; Amir Shroufi; Lara Vojnov; Jennifer Cohn; Teri Roberts; Tom Ellman; Kimberly Bonner; Christine Rousseau; Geoff Garnett; Valentina Cambiano; Fumiyo Nakagawa; Deborah Ford; Loveleen Bansi-Matharu; Alec Miners; Jens D Lundgren; Jeffrey W Eaton; Rosalind Parkes-Ratanshi; Zachary Katz; David Maman; Nathan Ford; Marco Vitoria; Meg Doherty; David Dowdy; Brooke Nichols; Maurine Murtagh; Meghan Wareham; Kara M Palamountain; Christine Chakanyuka Musanhu; Wendy Stevens; David Katzenstein; Andrea Ciaranello; Ruanne Barnabas; R Scott Braithwaite; Eran Bendavid; Kusum J Nathoo; David van de Vijver; David P Wilson; Charles Holmes; Anna Bershteyn; Simon Walker; Elliot Raizes; Ilesh Jani; Lisa J Nelson; Rosanna Peeling; Fern Terris-Prestholt; Joseph Murungu; Tsitsi Mutasa-Apollo; Timothy B Hallett; Paul Revill
Journal:  Nature       Date:  2015-12-03       Impact factor: 49.962

2.  Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa.

Authors:  Maya L Petersen; Linh Tran; Elvin H Geng; Steven J Reynolds; Andrew Kambugu; Robin Wood; David R Bangsberg; Constantin T Yiannoutsos; Steven G Deeks; Jeffrey N Martin
Journal:  AIDS       Date:  2014-09-10       Impact factor: 4.177

3.  CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.

Authors:  Christopher J Hoffmann; Jean Maritz; Gert U van Zyl
Journal:  Trop Med Int Health       Date:  2015-12-10       Impact factor: 2.622

4.  A nurse-led intervention to improve management of virological failure in public sector HIV clinics in Durban, South Africa: A pre- and post-implementation evaluation.

Authors:  H Sunpath; S Pillay; T Hatlen; R A Murphy; V C Marconi; M-Y S Moosa; K Naidoo; M J Siedner
Journal:  S Afr Med J       Date:  2021-03-31

5.  Urgent need to improve programmatic management of patients with HIV failing first-line antiretroviral therapy.

Authors:  H Sunpath; T J Hatlen; M-Y S Moosa; R A Murphy; M Siedner; K Naidoo
Journal:  Public Health Action       Date:  2020-12-21

6.  High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.

Authors:  Justen Manasa; Richard J Lessells; Andrew Skingsley; Kevindra K Naidu; Marie-Louise Newell; Nuala McGrath; Tulio de Oliveira
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

7.  CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.

Authors:  Lee Fairlie; Brad Karalius; Kunjal Patel; Russell B van Dyke; Rohan Hazra; Miguel A Hernán; George K Siberry; George R Seage; Allison Agwu; Andrew Wiznia
Journal:  AIDS       Date:  2015-10-23       Impact factor: 4.177

8.  Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.

Authors:  Andrew Phillips; Valentina Cambiano; Fumiyo Nakagawa; Travor Mabugu; Travor Magubu; Alec Miners; Debbie Ford; Deenan Pillay; Andrea De Luca; Jens Lundgren; Paul Revill
Journal:  PLoS One       Date:  2014-10-07       Impact factor: 3.240

9.  Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch.

Authors:  Victoria Johnston; Karen Cohen; Lubbe Wiesner; Lynn Morris; Johanna Ledwaba; Katherine L Fielding; Salome Charalambous; Gavin Churchyard; Andrew Phillips; Alison D Grant
Journal:  J Infect Dis       Date:  2013-08-13       Impact factor: 5.226

10.  Impact and programmatic implications of routine viral load monitoring in Swaziland.

Authors:  Kiran Jobanputra; Lucy Anne Parker; Charles Azih; Velephi Okello; Gugu Maphalala; Guillaume Jouquet; Bernhard Kerschberger; Calorine Mekeidje; Joanne Cyr; Arnold Mafikudze; Win Han; Johnny Lujan; Roger Teck; Annick Antierens; Johan van Griensven; Tony Reid
Journal:  J Acquir Immune Defic Syndr       Date:  2014-09-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.